Kim DD, Fineman MS, Baron AD: Effects of exenatide(exendin-4) on glycemic control over 30 weeks in pa-tients with type 2 diabetes treated with metforminand a sulfonylurea. Diabetes Care 2005;28:1083–1091. 49. Fineman MS, Shen LZ, Taylor K, Kim DD, Baron AD: Effectiveness of progressive dose-escalation of exe-natide (exendin-4) in reducing dose-limiting side ef-fects in subjects with type 2 diabetes. Diabetes MetabRes Rev 2004;20:411–417. Address reprint requests to: Dennis Kim, M.D. Senior Director, Medical Affairs Amylin Pharmaceuticals, Inc. 9360 Towne Centre Drive San Diego, CA 92121 E-mail: dkim@amylin.comEXENATIDE DOSE-RANGING STUDY 4775678_05_p467-477  5/18/05  12:44 PM  Page 477